Sonoma Pharmaceuticals (SNOA) Payables (2011 - 2026)

Sonoma Pharmaceuticals' Payables history runs 16 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• On a quarterly basis, Payables rose 110.91% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $2.5 million, a 110.91% increase from a year earlier, with the FY2026 full-year figure at $2.5 million, up 110.91% from the prior year.
• Payables climbed to $2.5 million in Q1 2026 per SNOA's latest filing, from $1.6 million in the prior quarter.
• Across five years, Payables topped out at $2.5 million in Q1 2026 and bottomed at $864000.0 in Q4 2023.
• The 5-year median for Payables is $1.9 million (2024), against an average of $1.8 million.
• Across the five-year window, Payables sank 60.75% in 2023 and surged 121.76% in 2024, its largest moves.
• Year by year, Payables stood at $2.2 million in 2022, then sank by 60.75% to $864000.0 in 2023, then jumped by 121.76% to $1.9 million in 2024, then retreated by 14.09% to $1.6 million in 2025, then surged by 50.3% to $2.5 million in 2026.
• Per Business Quant, the three latest SNOA Payables figures stand at $2.5 million (Q1 2026), $1.6 million (Q4 2025), and $1.5 million (Q3 2025).